baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LUPIN LIMITED Stock/ INE326A01037 /

07/06/2024 11:59:59	Chg. +22.30	Volume	Bid12:20:28	Ask12:13:17	High	Low
1,629.55INR	+1.39%	799,852 Turnover: 1.31 bill.	1,629.55Bid Size: 1	1,629.55Ask Size: 19	1,651.00	1,618.20

GlobeNewswire 09/02/2022 Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

GlobeNewswire 04/11/2021 Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adult...

GlobeNewswire 16/02/2021 Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symp...

GlobeNewswire 08/12/2020 Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia ...

GlobeNewswire 08/06/2020 US FDA Grants Mexiletine Orphan Drug Designation

GlobeNewswire 03/06/2020 Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

GlobeNewswire 01/02/2019 Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia ...

GlobeNewswire 08/01/2019 Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myot...

LUPIN LIMITED Stock/ INE326A01037 /

If you wish to receive reply to your feedback, please provide your email address.